5 Lessons Doctors Can Take From FDA's Big Stem-Cell Win

Law360, New York (February 7, 2014, 7:22 PM EST) -- The D.C. Circuit on Tuesday delivered a loud wake-up call to stem cell clinics when it endorsed strong oversight by the U.S. Food and Drug Administration, but doctors can take comfort in a number of exceptions and strategies that could limit the ruling's reach.

At issue were treatments by Colorado-based Regenerative Sciences LLC that involve extracting cells and letting them multiply in a laboratory setting — a process the appeals court said crossed the line into drug manufacturing, triggering FDA scrutiny. That's a costly setback for clinics, but there is reason to believe they'll find ways around the decision by moving...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!